Denneroll attempts to protect its chiropractic devices with new suit
Australia-based spinal orthotics device company files suit against ChiroLux | Alleges infringement of one of its chiropractic products aimed at relieving neck pain.
ChiroLux was hit with a patent infringement lawsuit accusing it of infringing orthotic devices designed to alleviate neck pain.
Denneroll Holdings filed the suit in the US District Court for the Southern District of Texas, alleging ChiroLux violated its orthotic device patent.
Australia's Denneroll Holdings sells and markets products for effective spinal healthcare, including the Cervical Denneroll orthotic devices.
These devices, invented by Adrian Dennewald, are designed to relieve pain and muscle tension associated with abnormal curvature of the neck.
Denneroll products are sold worldwide, including the US, Australia, New Zealand and the UK, and are purchased by chiropractors and patients to use in the prevention and treatment of poor spinal health.
The Cervical Denneroll products are cervical orthotic devices for relieving pain and muscle tension associated with abnormal curvature of a person’s neck.
The patent in question, US patent number 11,419,440, is owned by Denneroll Holdings and was approved in August 2022 by the Patent Trial and Appeal Board—protecting the Cervical Denneroll orthotic devices.
The complaint alleged that Washington-based ChiroLux, which also sells products to chiropractors and patients, through its product ChiroLux Curv has infringed on the '440 Patent.
Denneroll said, in its complaint, ChiroLux received notice of the patent of its infringement multiple times, even as early as the date Denneroll began making its product with the patent.
Despite allegedly having notice of its infringement, ChiroLux continued to sell and import its orthotic devices within the US.
Denneroll Holdings brought two counts of direct infringement and indirect infringement against ChiroLux.
The complaint sought a judgment declaring infringement, injunctive relief, compensatory damages, and other relief as the court deems appropriate.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk